Parameter | Eyes (n=64) | Per cent |
---|---|---|
Primary intravenous chemotherapy regimen* | ||
Number of treatments | ||
Median (mean, range) | 6 (6, 2–6) | |
Time range (days) | ||
Median (mean, range) | 120 (123, 33–160) | |
Early treatment failure (no response to chemotherapy) | 8 | 12.5 |
Total number of additional treatments† | ||
Median (mean, range) | 3 (6, 0–24) | |
Number of eyes having additional treatments | ||
No additional treatments | 3 | 5 |
Additional diode laser and/or cryotherapy | 50 | 78 |
During systemic chemotherapy courses | 23 | 46 |
Ruthenium plaque radiotherapy | 12 | 19 |
Intra-ophthalmic artery chemotherapy | 20‡ | 31 |
Median number of treatments (mean, range) | 3 (3, 1–6) | |
Intravitreal chemotherapy | 4§ | 6 |
Median number of treatments (mean, range) | 2 (3, 1–6) | |
Second line systemic chemotherapy | 2 | 3 |
External beam radiotherapy | 5 | 8 |
*Vincristine, etoposide, carboplatin.
†Including diode laser, cryotherapy, plaque radiotherapy and salvage intravenous chemotherapy, excluding external beam radiotherapy and secondary enucleation.
‡First patients treated in 2009.
§First patient treated in 2014.